Effect of DC-CIK immunotherapy combined with chemotherapy on patients with advanced breast cancer |
| Jing Wang Zhengliang Chen Chenfei Hu |
| Qinhuai Medical District, General Hospital of Eastern Theater Command, Nanjing, Jiangsu, 210000, China |
Abstract : Objective To analyze the effectiveness of DC-CIK immunotherapy combined with chemotherapy in patients with advanced breast cancer. Methods A total of 64 patients with advanced breast cancer admitted to our hospital from March —— March 2023 were included in the study, divided into two groups based on different treatment methods: traditional group and combined group, each consisting of 32 cases; the traditional group received conventional chemotherapy, while the combined group received both conventional chemotherapy and DC-CIK immunotherapy. The treatment outcomes and immune markers were compared between the two groups. Results Compared to the traditional group, the overall effective rate of treatment was significantly higher in the combined group (P<0.05); compared to the traditional group, the levels of CD3+, CD3+/CD4+, and NK cells were all better in the combined group (P<0.05). Conclusion In the treatment of advanced breast cancer, combining DC-CIK immunotherapy with chemotherapy can achieve ideal therapeutic effects and improve immune markers; therefore, it is worth actively promoting and scientifically applying this approach in the field.
Keywords DC-CIK immunotherapy; chemotherapy; advanced breast cancer; effect
|
References
[1] Wang Xulin, Li Huijuan, Wang Lihua, et al. The killing effect of Sophoridine combined with DC-CIK cells on breast cancer cells [J]. Chinese Journal of Clinical Pharmacology, 2023,39(16):2311-2315.
[2] Miao Peitian, Tong Zhongsheng, Bao Shuangzhen. Efficacy of DC-CIK combined with FAC chemotherapy in the treatment of breast cancer and its effect on the immune function and tumor marker level of patients [J]. Chinese Journal of Maternal and Child Health, 2021,36(9):5.
[3] Zhang Yang. Effects of DC-CIK cell combined GP regimen on serum GAS5 and MALAT1 levels in patients with advanced triple-negative breast cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2020 (S1):37,39-37,39.
|
|
|
Document Retrieval Certificate / Proof of Publication Indexing
Author Contribution Statement / Certificate of Authorship Contribution
Peer Review Report / Peer Review Comments
Conflict of Interest
The author declares no conflict of interest.
|
|
